期刊文献+

罗格列酮对骨髓瘤细胞HIF1α和IGF1mRNA表达的影响及其可能机制

Effect of rosiglitazone on the expression of HIF1α and IGF1 mRNA in myeloma
原文传递
导出
摘要 目的 观察罗格列酮作用后骨髓瘤细胞HIF1α和IGF1 mRNA表达水平,探讨罗格列酮抑制骨髓瘤血管形成的可能机制.方法 以骨髓瘤细胞系RPMI 8226细胞及5例初诊多发性骨髓瘤患者骨髓浆细胞(CD138免疫磁珠筛选,作为骨髓瘤原代细胞)为研究对象,采用RT-PCR法检测用不同浓度(10、20、40 μmol/L)罗格列酮处理前后骨髓瘤细胞HIF1α、IGF1 mRNA表达水平;采用Westernblot法检测AKT和ERK蛋白磷酸化和非磷酸化表达的情况.同时以5例缺铁性贫血患者的骨髓单个核细胞为对照组.结果 RPMI8226细胞和骨髓瘤原代细胞HIF1α和IGF1 mRNA表达显著高于对照组.罗格列酮浓度为20 μmol/L处理48 h后,与对照组相比,RPMI 8226细胞中HIF1α、IGF1 mRNA相对表达水平分别由1.21±0.08和0.62±0.06降至0.75±0.06和0.32±0.04,骨髓瘤原代细胞中HIF1α、IGF1mRNA表达水平分别由2.02±0.16和1.92±0.13降至0.53±0.04和0.58±0.03,差异均有统计学意义(P值均<0.05),且呈剂量依赖性;10、20、40 μmol/L罗格列酮均可抑制RPMI8226细胞pAKT、pERK蛋白的表达,然而对骨髓瘤原代细胞T-AKT和T-ERK蛋白表达没有明显影响.结论 罗格列酮可抑制HIF1α、IGF1 mRNA的表达,降低pAKT和pERK蛋白的表达可能是其抑制肿瘤血管形成机制之一. Objective To observe the effect of rosiglitazone (RGZ) on the mRNA expression of HIF1α and IGF1 genes in the myeloma cells and explore possible mechanism of angiogenesis inhibition.Methods Human myeloma cell line RPMI 8226 and primary myeloma cells from five patients enriched by using CD 138 immunomagnetic beads were treated with different concentrations (10,20,40 μmol/L)of RGZ.The mRNA expression of HIF1α and IGF1 was analyzed in cells treated with RGZ after 48h by RT-PCR,The levels of phosphorylated AKT and ERK proteins were detected by Western blotting.Bone marrow mononuclear cells from five patients with iron deficiency anemia were regarded as control.Results Higher mRNA expression of HIF1α and IGF1 genes in RPMI8226 and in primary myeloma cells was showed as compared to those in control.Treated with RGZ of 20 μmol/L after 48 h,the mRNA expression of HIF1α (1.21±0.08 vs 0.75±0.06) and IGF1 (0.62±0.06 vs 0.32±0.04) in RPMI8226 cells was declined as compared to those without RGC treatment.The same declination was also seen in in primary myeloma cells (HIF 1 α:2.02±0.16 vs 0.53±0.04; IGF 1:1.92±0.13 vs 0.58±0.03).RGZ could inhibit the expression of pAKT and pERK,nor the total AKT and ERK proteins,in RPMI8226 cells in a dose-dependent manner at the concentration of 10 μmol/L,20 μmol/L,and 40 μmol/L.Conclusions RGZ could inhibit the mRNA expression of HIF 1 α and IGF 1.Inhibition of angiogenesis by RGZ may be associated with down-regulation of pAKT and pERK expression.
出处 《中华血液学杂志》 CAS CSCD 北大核心 2014年第7期641-644,共4页 Chinese Journal of Hematology
基金 江苏省自然科学基金(BK2012610) 江苏省高校自然科学基金(SZ12306612) 苏州市社会发展基金(SYS201134)
关键词 罗格列酮 多发性骨髓瘤 基因 HIF1α 基因 IGF1 Rosiglitazone Multiple myeloma Gene, HIF1α Gene, IGF1
  • 相关文献

参考文献15

  • 1Robbins GT, Nie D. PPAR gamma, bioactive lipids, and cancer progression [J]. Front Biosci (landmark Ed), 2012, 17: 1816-1834.
  • 2Xin B, Yokoyama Y, Shigeto T, et al. Inhibitory effect of meloxi- cam, a selective cyclooxygenase-2 inhibitor, and ciglitazone, aperoxisome proliferator-activated receptor gamma ligand, on the growth of human ovarian cancers[ J ]. Cancer, 2007, 110 (4): 791-800.
  • 3黄海雯,陈萍,李炳宗,傅晋翔,李军,张晓慧,刘睿,范银银,张宏,Howard C.H. Chow,Anska Y. H. Leung,Raymond Liang.罗格列酮和全反式维甲酸对多发性骨髓瘤裸鼠移植瘤生长及血管形成的影响[J].中华肿瘤杂志,2012,34(9):652-657. 被引量:5
  • 4黄海雯,吴德沛,陈广华,常惠荣,Chow HCH,Leung AYH,Liang R.罗格列酮与全反式维甲酸联合对骨髓瘤细胞增殖抑制作用及其机制探讨[J].中华血液学杂志,2009,30(4):242-246. 被引量:5
  • 5Menu E, Kooijman R, Van Valckenborgh E, et al. Specific roles for the PI3K and the MEK-ERK pathway in IGF-1- stimulated chemotaxis, VEGF secretion and proliferation of multiple myeloma cells: study in the 5T33MM model[J]. Br J Cancer, 2004, 90(5):1076-1083.
  • 6. Zhang J, Sattler M, Tonon G, et al. Targeting angiogenesis via a c- Myc/hypoxia- inducible factor- lalpha- dependent pathway in multiple myeloma[ J]. Cancer Res, 2009, 69( 12):5082-5090.
  • 7Giatromanolaki A, Bai M, Margaritis D, et al. Hypoxia and activated VEGF/receptor pathway in multiple myeloma [J]. Anticancer Res, 2010, 30(7):2831-2836.
  • 8Martin SK, Diamond P, Williams SA, et al. Hypoxia-inducible factor-2 is a novel regulator of aberrant CXCL12 expression in multiple myeloma plasma ceils [J]. Haematologica, 2010, 95 (5) :776-784.
  • 9Colla S, Storti P, Donofrio G, et al. Low bone marrow oxygen tension and hypoxia- inducible factor- 1 αoverexpression charac- terize patient swith multiple myeloma: role on the transcription- al and proangiogenic profiles of CD 138 (+) cells [ J]. Leukemia, 2010, 24(11):1967-1970.
  • 10Mitsiades CS, Mitsiades NS, McMullan CJ, et al. Inhibition of the insulin- like growth factor receptor- 1 tyrosine kinase activi- ty as a therapeutic strategy formultiple myeloma, other hemato- logic malignancies, and solid tumors [J]. Cancer Cell, 2004, 5 (3):221-230.

二级参考文献18

  • 1Huang H, Wu D. Fu J, el al. ALl-trans relinoic acid can intensify the growth inhibition amt diffentiation induction effect ofrosiglitazoue on multiple myeloma cells. Eur J Haematol, 2009, 83 : 191-202.
  • 2Bresalier RS, Ho SB, Schoeppner HL, et al. Enhanced sialylation of mucin-associated carbohydrate structures in human colon cancer metastasis. Gastroenterology, 1996, 110:1354-1367.
  • 3Weidner N, Semple JP, Welch WR, et al. Tumor angiogenesis and metastasis--correlation in invasive breast carcinoma. N Eng J Med, 1991, 324 : 1-8.
  • 4Tontonoz P, Spiegelman BM. Fat and beyond: the diverse biology of PPARgamma. Annu Rev Biochem, 2008, 77:289-312.
  • 5Nolte RT, Wisely GB, Westin S, et al. Ligand binding and co- activator assembly of the peroxisome proliferator-activated receptor- gamma. Nature, 1998, 395:137-143.
  • 6Mangelsdorf D J, Ong ES, Dyck JA, et al. Nuclear receptor that identifies a novel retinoic acid response pathway. Nature, 1990, 345 : 224-229.
  • 7Shaik MS, Chatterjee A, Jackson T, et al. Enhancement of antitumor activity of docetaxel by celecoxib in lung tumors. Int J Cancer, 2006, 118:396-404.
  • 8Xin B, Yokoyama Y, Shigeto T, et al. Inhibitory effect of meloxicam, selective cyclooxygenase-2 inhibitor, and ciglitazorle, a peroxisome proliferator-activated receptor gamma ligand, on the growth of human ovarian cancers. Cancer, 2007, 110:791-800.
  • 9Possati L, Rocchetti R, Talevi S, et al. The role of peroxisomeproliferator-activated receptor gamma in bladder cancer in relation to angiogenesis and progression. Gen Pharmacol, 2000, 35:269- 275.
  • 10Haslmayer P, Thalhammer T, yager W, et al. the pemxlsome proliferator- activated receptor garrma ligand 15-deoxy-Deltal2, 14-prostaglandin J2 induces vascular endothelial growth factor in the hormone- independent prostate cancer cell line PC 3 and the urinary bladder carcinoma cell line 5637. Int J Oncol, 2002, 21:915-920.

共引文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部